What is BPC-157?

Structure and sequence

BPC-157 is a synthetic pentadecapeptide, a chain of fifteen amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is manufactured by solid-phase peptide synthesis, the standard method for producing research peptides at defined purity, described in more detail in our guide to what research peptides are.

Origin: a fragment of a gastric protein

The name BPC stands for body protection compound, reflecting its origin, as described by the research group that developed it, as a partial sequence derived from a protein identified in human gastric juice. Researchers isolated this stable core fragment because, unlike many peptides, it is unusually resistant to degradation in gastric fluid, a property that has made it a subject of interest in laboratory studies examining peptide stability alongside its signalling activity.

Pathways studied in the published literature

Laboratory research on BPC-157, conducted in cell cultures and animal models, has examined its interaction with several signalling pathways, including studies of angiogenesis (the formation of new blood vessels), growth factor signalling pathways such as those involving VEGF, and cellular processes relevant to tissue repair mechanisms at a molecular level. Nearly all of this literature is preclinical, meaning it describes laboratory and animal model findings. A few small, uncontrolled human reports have been published, and a Phase 2 trial (NCT07437547) has been recruiting since February 2026; no effect has been established in humans.

As with any research compound, findings from cell or animal models describe what is observed under specific experimental conditions and do not by themselves establish an effect in humans.

How BPC-157 is supplied for research

As a research compound, BPC-157 is characterised the same way as any other synthetic peptide, typically with purity assessed by HPLC and identity checked by mass spectrometry or against a reference standard. Celyfe's published WOLVERINE certificate (batch C26071) is a third-party HPLC report giving 99% purity and a measured BPC-157 content of 4.53mg/ml, about 91% of the 5mg/ml label; it does not include mass spectrometry. Celyfe includes BPC-157 in its WOLVERINE Pen (paired with TB-500), GLOW Pen and KLOW Pen (each alongside GHK-Cu, TB-500, and in KLOW's case also KPV), each at 15mg per 3ml cartridge, shipped cold-chain and stored refrigerated between 2 and 8 degrees Celsius.

BPC-157 alongside TB-500

BPC-157 is frequently studied and sold alongside TB-500, another compound examined in tissue-repair-adjacent research, despite the two having quite different structural origins. Our dedicated comparison, BPC-157 vs TB-500, sets out how their studied mechanisms differ and why they are commonly paired in a single formulation such as the WOLVERINE Pen.

Research use only

BPC-157 supplied by Celyfe is intended for laboratory and research use only. It is not an approved medicine, and nothing in this guide describes or implies its use in or on a human or animal body.